Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeCivaTech Oncology IncMedical Specialists Report Updates with CivaSheet® Directional Brachytherapy in the Treatment of Sarcoma

Medical Specialists Report Updates with CivaSheet® Directional Brachytherapy in the Treatment of Sarcoma

Physicians report CivaSheet®, a unidirectional LDR brachytherapy implant made by CivaTech Oncology, demonstrates up to three-year local control in recurrent retroperitoneal sarcomas when implanted during surgical resection. The crude cumulative incidence of local recurrence (LR) is 26%. To date, 21 sarcoma patients have been implanted with CivaSheet at six medical centers. Sarcoma patients tolerate the implant well with no complications following surgery. None of the 21 patients (0/21) have demonstrated local recurrence. There were no reported incidences of acute or late radiation toxicity despite the surrounding organs at risk, including small bowel, ureter and kidneys. The directional source distribution allows for safe re-irradiation or adjuvant brachytherapy boost radiation therapy in patients who have had maximum EBRT dose.

A recent publication details a patient with more than 3 years follow up. This report demonstrates “CivaSheet was associated with durable local control and significant reduction in doses to OARs including bowel, rectum, and bladder.” Additionally, “the bioabsorbability, flexibility, and easy identification on CT imaging allow this device to treat tumors in irregularly shaped cavities such as the pelvic sidewall and retroperitoneum.” The uni-directional design protects healthy tissues allowing a targeted dose with no toxicity. The novel polymer encapsulation allows unprecedented dose uniformity. “Moreover, the directional nature of this device helps increase the therapeutic ratio by avoiding unnecessary irradiation of OARs.” Furthermore, “CivaSheet expands IORT capabilities in a resource independent manner.” Application of uni-directional, planar Pd-103 LDR brachytherapy technology is safe and easy and should be considered as a standard option to escalate the dose to high-risk margins after resection.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy